Envoy Medical, Inc.
Envoy Medical, Inc. is classified under Financials / Banks and appears not currently profitable on the latest normalized snapshot.
Business. Envoy Medical, Inc. (Nasdaq: COCH) is a health care company operating within the advanced medical equipment and technology industry. The firm is headquartered in the United States and is primarily listed on the Nasdaq stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Peers
- DividendDividend USD 1.75/sh2026-09-25 · Bank of America (BAC)
- EarningsQ3 2026 earnings (expected)2026-10-13 · estimated · JPMorgan Chase (JPM)
- EarningsQ3 2026 earnings (expected)2026-10-13 · estimated · Citigroup (C)
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Envoy Medical, Inc. (COCH) has recorded a notable addition to its shareholder base, marking the first material change identified for the ticker. As of March 31, 2026, investor ID 931 added a position of 5 shares, valued at approximately $0.000003 million. This activity was detected on June 20, 2026, and represents a weight of roughly 1.44e-09 percent of the total holdings, signaling a minimal but distinct entry into the company’s ownership structure. This development is significant as it constitutes the first analysis basis for COCH, with no prior data available for delta computation. The absence of previous material changes means this holder addition serves as the initial benchmark for tracking investor interest. Consequently, the significance of this event lies in its role as the starting point for monitoring future shifts in ownership rather than indicating a substantial change in market sentiment or capital allocation. From a broader company perspective, Envoy Medical currently reports zero officers and zero analyst coverage, alongside no index memberships. The company maintains a top holder count of 11, suggesting a concentrated but small base of investors. The addition of investor ID 931 does not alter the fundamental lack of institutional analyst attention or executive leadership visibility as defined by the current data set. The material nature of this change is limited by the negligible share count and value involved. With no cross-source signals or sagas to provide additional context, the event remains an isolated data point. Investors should view this as a baseline establishment for COCH’s holder dynamics, with future significance dependent on whether this initial entry expands or if other notable changes emerge in subsequent reporting periods.
Signals & dispatch
Composite-score breakdown
Synthesis
Envoy Medical, Inc. (Nasdaq: COCH) is a health care company operating within the advanced medical equipment and technology industry. The firm is headquartered in the United States and is primarily listed on the Nasdaq stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Envoy Medical, Inc. (COCH) is currently classified as Commercial Banks within Banks (Financials). Classification confidence: 0.81 (rule-based classification). Capital structure on the latest snapshot: total assets 29,822,000 USD, total equity 10,161,000, short-term debt 0, long-term debt 0. Net cash position is approximately 4,218,000 USD. Self-calculated market cap is 47,668,525 USD (market_price × shares_outstanding_diluted). Profitability profile: revenue 39,000, gross profit 0, operating income -5,959,000, net income -4,351,000. Return on equity ~-233.8%. Return on assets ~-79.7%. Operating-cash-flow to net-income ratio is 0.77. Risk profile from automated assessment: liquidity risk high, dilution risk high. Flags: Diluted share count is materially above the basic share count.; Filings reference going-concern or substantial-doubt language.; Source documents mention dilution or offering risk.. Recent news context: [TRIGGER] allocator_boost: allocator_boost (allocator) on COCH — watcher=allocator; producer_version=ws49-p2a-v2; plan_date=2026-07-29; rank=22; ev=8.615075; company_id=2b666385-dcd6-47b7-b7c7-20bec1e7f666; term_contributions={'event_proximity': 2.456192, 'gradability': 2.0, 'staleness': 4.158883, 'credibility_interest': 0.0}; days_since_analysis=63; pending_promises=0; reason=Allocator coverage boost rank #22 EV=8.615075 for COCH (hot+stale; days_since=63); calendar_week={'next_event_date': '2026-07-30', 'days_until': 1, 'bases': ['expected (estimated date)'], 'in_plan_rows': True, 'never_analyzed': False}; contributing_watchers=allocator (source=allocator; url=allocator:2026-07-29:COCH). Additional context: allocator_boost: watcher=allocator; producer_version=ws49-p2a-v2; plan_date=2026-07-29; rank=22; ev=8.615075; company_id=2b666385-dcd6-47b7-b7c7-20bec1e7f666; term_contributions={'event_proximity': 2.456192, 'gradability': 2.0, 'staleness': 4.158883, 'credibility_interest': 0.0}; days_since_analysis=63; pending_promises=0; reason=Allocator coverage boost rank #22 EV=8.615075 for COCH (hot+stale; days_since=63); calendar_week={'next_event_date': '2026-07-30', 'days_until': 1, 'bases': ['expected (estimated date)'], 'in_plan_rows': True, 'never_analyzed': False}; contributing_watchers=allocator. Comparable peers identified within the same class: JPMorgan Chase, Bank of America, Citigroup.
Envoy Medical, Inc. (COCH) has recorded a notable addition to its shareholder base, marking the first material change identified for the ticker. As of March 31, 2026, investor ID 931 added a position of 5 shares, valued at approximately $0.000003 million. This activity was detected on June 20, 2026, and represents a weight of roughly 1.44e-09 percent of the total holdings, signaling a minimal but distinct entry into the company’s ownership structure. This development is significant as it constitutes the first analysis basis for COCH, with no prior data available for delta computation. The absence of previous material changes means this holder addition serves as the initial benchmark for tracking investor interest. Consequently, the significance of this event lies in its role as the starting point for monitoring future shifts in ownership rather than indicating a substantial change in market sentiment or capital allocation. From a broader company perspective, Envoy Medical currently reports zero officers and zero analyst coverage, alongside no index memberships. The company maintains a top holder count of 11, suggesting a concentrated but small base of investors. The addition of investor ID 931 does not alter the fundamental lack of institutional analyst attention or executive leadership visibility as defined by the current data set. The material nature of this change is limited by the negligible share count and value involved. With no cross-source signals or sagas to provide additional context, the event remains an isolated data point. Investors should view this as a baseline establishment for COCH’s holder dynamics, with future significance dependent on whether this initial entry expands or if other notable changes emerge in subsequent reporting periods.
- Return on equity is about -233.8%.
- Debt to equity is about 0.0x.
- [TRIGGER] allocator_boost: allocator_boost (allocator) on COCH — watcher=allocator; producer_version=ws49-p2a-v2; plan_date=2026-07-29; rank=22; ev=8.615075; company_id=2b666385-dcd6-47b7-b7c7-20bec1e7f666; term_contributions={'event_proximity': 2.456192, 'gradability': 2.0, 'staleness': 4.158883, 'credibility_interest': 0.0}; days_since_analysis=63; pending_promises=0; reason=Allocator coverage boost rank #22 EV=8.615075 for COCH (hot+stale; days_since=63); calendar_week={'next_event_date': '2026-07-30', 'days_until': 1, 'bases': ['expected (estimated date)'], 'in_plan_rows': True, 'never_analyzed': False}; contributing_watchers=allocator (source=allocator; url=allocator:2026-07-29:COCH)
- Likely peers from the same classification include JPMorgan Chase, Bank of America, Citigroup.
- Companyfacts coverage was partial; recent filing facts backfilled cash_and_equivalents, shares_outstanding_basic.
- CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (In thousands, except share and per share amounts) March 31, December 31, 2026 2025 (unaudited) Current assets: Cash $ 25,251 $ 3,739 Accounts receivable, net 31 34 Other receivable 17 19 Inventories 1,490 1,546 Prepaid expenses and other current assets 893 941 Total current assets 27,682 6,279 Property and equipment, net 962 1,035 Operating lease right-of-use asset (related party) 853 886 Prepaid expenses and other assets 325 358 Total assets $ 29,822 $ 8,558 Liabilities, mezzanine equity, and stockholders’ equity (deficit) Current liabilities: Accounts payable $ 1,700 $ 2,920 Accrued expenses 9,653 7,639 Forward purchase agreement warrant liability 37 24 Product warranty liability, current portion 264 287 Operating lease liability, current portion (related party) 178 174 Other current liabilities 379 518 Total current liabilities 12,211 11,562 Product warranty liability, net of current portion 1,550 1,605 Operating lease liability, net of current portion (related party) 711 745 Private warrant liability 3,830 5,835 Publicly traded warrant liability 941 551 Other liability 27 27 Total liabilities 19,270 20,325 Commitments and contingencies (see Note 13) Mezzanine equity Warrants issued to placement agent as part of the 2025 Offerings (see Note 9) 391 391 Stockholders’ equity (deficit) Series A Preferred Stock, $ 0.0001 par value; 100,000,000 shares authorized and 10,000,000 shares designated as of March 31, 2026 and December 31, 2025; 4,126,667 shares issued and outstanding as of March 31, 2026 and December 31, 2025 - - Class A Common Stock, $ 0.0001 par value; 400,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 76,881,110 shares issued and outstanding as of March 31, 2026 and 28,934,960 shares issued and outstanding as of December 31, 2025 8 3 Additional paid-in capital 329,371 301,355 Accumulated deficit ( 319,097 ) ( 313,396 ) Accumulated other comprehensive loss ( 121 ) ( 120 ) Total stockholders’ equity (deficit) 10,161 ( 12,158 ) Total liabilities, mezzanine equity, and stockholders’ equity (deficit) $ 29,822 $ 8,558 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
Bull / Bear case
Generated · model-assistedAnalysts project 783.8% upside to a $6.00 mean price target, signaling strong potential for significant share price appreciation.
The company maintains a zero debt-to-equity ratio, ranking above the median of 0.11 within its peer cohort.
Capital expenditure intensity of 0.74 is classified as best-in-class compared to the cohort median of -0.04.
Net income improved by 12.5% year-over-year in FY2025, indicating a slight reduction in absolute losses.
Operating income improved by 13.5% year-over-year in FY2025, suggesting marginal stabilization in core operational performance.
The company faces high dilution and liquidity risks, threatening capital structure stability and operational continuity.
Revenue declined at a 15.6% CAGR from FY2023 to FY2025, demonstrating a persistent and significant top-line contraction.
Net margin of -98.6% places the company in the bottom quartile of its 192-company peer cohort.
Operating margin of -92.4% ranks in the bottom quartile among 193 peers, highlighting severe operational inefficiency.
A current ratio of 0.54 indicates insufficient short-term assets to cover liabilities, exacerbating high liquidity risk.
In focus — financials by report
Revenue $39.0k; Operating income -$6.0M.
- ▍Revenue $39.0k
- ▍Operating income -$6.0M
- ▍Net margin -11156.4%
Revenue $166.0k; Operating income -$15.9M.
- ▍Revenue $166.0k
- ▍Operating income -$15.9M
- ▍Net margin -10343.4%
Revenue $124.0k; Operating income -$10.2M.
- ▍Revenue $124.0k
- ▍Operating income -$10.2M
- ▍Net margin -8619.4%
Revenue $241.0k; Operating income -$22.3M.
- ▍Revenue $241.0k
- ▍Operating income -$22.3M
- ▍Net margin -9857.3%
Revenue $225.0k; Operating income -$19.3M.
- ▍Revenue $225.0k
- ▍Operating income -$19.3M
- ▍Net margin -9242.2%
Revenue $225.0k; Operating income -$19.3M.
- ▍Revenue $225.0k
- ▍Operating income -$19.3M
- ▍Net margin -9242.2%
Revenue $316.0k; Operating income -$18.4M.
- ▍Revenue $316.0k
- ▍Operating income -$18.4M
- ▍Net margin -9464.6%
Revenue $316.0k; Operating income -$18.4M.
- ▍Revenue $316.0k
- ▍Operating income -$18.4M
- ▍Net margin -9469.0%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,29 |
| Revenue | —no estimate | —no estimate | 219,000 USD |
| Operating income | —no estimate | —no estimate | -21,5M USD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Diluted share count is materially above the basic share count.
- Filings reference going-concern or substantial-doubt language.
- Source documents mention dilution or offering risk.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Derivative transactions
- Director, Chief Executive Officer · Stock Option (right to buy) → Class A Common StockAcquired 1 000 000 @ $0,63grant · 2026-06-19
- Director, Chief Executive Officer · Restricted Stock Units → Class A Common StockAcquired 1 000 000grant · 2026-06-19
- Director · Stock Option (Right to Buy) → Class A Common StockAcquired 100 000 @ $0,72grant · 2026-04-15
- Director · Warrant (right to buy) → Class A Common StockAcquired 187 500 @ $0,40purchase · 2026-02-12
- Interim CFO · Warrant (right to buy) → Class A Common StockAcquired 212 500 @ $0,40purchase · 2026-02-12
- Interim CFO · Warrant (right to buy) → Class A Common StockAcquired 127 500 @ $0,40purchase · 2026-02-12
- Director · Warrant (right to buy) → Class A Common StockAcquired 312 500 @ $0,40purchase · 2026-02-12
- Director · Warrant (right to buy) → Class A Common StockAcquired 96 150 @ $0,40purchase · 2026-02-12
- Director, Chief Executive Officer · Warrant (right to buy) → Class A Common StockAcquired 62 500 @ $0,40purchase · 2026-02-12
- Director · Warrant (right to buy) → Class A Common StockAcquired 57 690 @ $0,40purchase · 2026-02-12
- 10% owner · Warrant Shares (Series A-1) → Class A Common StockAcquired 11 250 000 @ $0,40purchase · 2026-02-12
- Director, Chief Executive Officer · Warrant (right to buy) → Class A Common StockAcquired 37 500 @ $0,40purchase · 2026-02-12
- 10% owner · Warrant Shares (Series A-2) → Class A Common StockAcquired 18 750 000 @ $0,40purchase · 2026-02-12
- Director · Warrant (right to buy) → Class A Common StockAcquired 1 000 000 @ $0,40purchase · 2026-02-12
- Director · Warrant (right to buy) → Class A Common StockAcquired 600 000 @ $0,40purchase · 2026-02-12
- Director, Chief Executive Officer · Stock Option (right to buy) → Class A Common StockAcquired 200 000 @ $0,53grant · 2026-02-05
- Interim CFO · Stock Option (right to buy) → Class A Common StockAcquired 15 000 @ $0,53grant · 2026-02-05
- Director · Stock Option (right to buy) → Class A Common StockAcquired 62 500 @ $0,81grant · 2025-12-03
- Director · Stock Option (right to buy) → Class A Common StockAcquired 25 000 @ $0,81grant · 2025-12-03
- Director · Stock Option (right to buy) → Class A Common StockAcquired 25 000 @ $0,81grant · 2025-12-03
- Director · Stock Option (right to buy) → Class A Common StockAcquired 25 000 @ $0,81grant · 2025-12-03
- Director · Stock Option (right to buy) → Class A Common StockAcquired 62 500 @ $0,81grant · 2025-12-03
- Director, 10% owner · Warrant (right to buy) → Class A Common StockDisposed 500 000 @ $1,24disposition · 2025-09-04
- Director, 10% owner · Warrant (right to buy) → Class A Common StockAcquired 750 000 @ $1,35grant · 2025-09-04
- Director, 10% owner · Warrant (right to buy) → Class A Common StockDisposed 750 000 @ $1,35disposition · 2025-09-04
Actions
Ask Handelsavisen
- Market data
- Regulatory filings
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Reference data
- Cash Conversion Ratiooperating_cash_flow / net_income
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Ev To Revenueenterprise_value / revenue
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Market Capmarket_price * shares_outstanding_diluted
- Envoy Medical, Inc. company facts · 2026-07-29
- Envoy Medical, Inc. 10-Q 2026-05-11 · 2026-07-29
- Envoy Medical, Inc. 10-K 2026-03-23 · 2026-07-29
- Envoy Medical, Inc. 10-Q 2025-11-10 · 2026-07-29
- Envoy Medical, Inc. 10-Q 2025-07-31 · 2026-07-29
- allocator_boost (allocator) on COCH · 2026-07-29
- Envoy Medical Inc Market data — analyst estimates · 2026-07-29
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2025-12-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2024-06-300,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
Insider activity
- Director, Chief Executive Officer · Class A Common StockOther 32 856 @ $0,60$20K · 2026-05-29
- Director · Class A Common StockBought 312 500 @ $0,40$125K · 2026-02-12
- Interim CFO · Class A Common StockBought 212 500 @ $0,40$85K · 2026-02-12
- Director · Class A Common StockBought 96 150 @ $0,40$38K · 2026-02-12
- Director · Class A Common StockBought 1 000 000 @ $0,40$400K · 2026-02-12
- Director, Chief Executive Officer · Class A Common StockBought 62 500 @ $0,40$25K · 2026-02-12
- 10% owner · Class A Common StockBought 18 750 000 @ $0,40$7,5M · 2026-02-12
- Director, Chief Executive Officer · Class A Common StockOther 18 105 @ $0,71$13K · 2025-11-28
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 17.4%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -33.1%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): -25.8%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 35.5%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): 7.1%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): 22.7%Derived (calculated)
- Debt-to-equity (FY 2025-12-31): -1.67xDerived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): -15.7%Derived (calculated)
- Current ratio (FY 2025-12-31): 0.54xDerived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -1.4%Derived (calculated)
- Net margin (FY 2025-12-31): -9,857.3%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): -14.2%Derived (calculated)
- Return on assets (FY 2025-12-31): -277.6%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 17.4%Derived (calculated)
- Return on equity (FY 2025-12-31): 195.4%Derived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): -81.7%Derived (calculated)
- Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): 17.8%Derived (calculated)
- R&D expense (annual): USD 12.49MSEC XBRL filing
- Cost of revenue (annual): USD 874KSEC XBRL filing
- EPS (basic) (annual): USD-PER-SHARES -1SEC XBRL filing
- Operating income (annual): USD -22.27MSEC XBRL filing
- Current assets (annual): USD 6.28MSEC XBRL filing
- Operating cash flow (annual): USD -18.2MSEC XBRL filing
- Current liabilities (annual): USD 11.56MSEC XBRL filing